{
    "xml": "<topic id=\"PHP7169\" outputclass=\"drug\" rev=\"1.11\" type=\"drug\" namespace=\"/drugs/ranibizumab\" basename=\"ranibizumab\" title=\"RANIBIZUMAB\">\n<title>RANIBIZUMAB</title>\n<body>\n<data name=\"vtmid\">425256004</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_961812892\" title=\"Vascular endothelial growth factor inhibitors\">Vascular endothelial growth factor inhibitors</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">   </data>\n</data>\n</body>\n<topic id=\"PHP38875\" outputclass=\"indicationsAndDose\" rev=\"1.14\" parent=\"/drugs/ranibizumab\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Neovascular (wet) age-related macular degeneration (specialist use only)</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By intravitreal injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>500&#8239;micrograms once a month, to be administered into the affected eye, monitor visual acuity monthly, continue treatment until visual acuity is stable for 3 consecutive months, thereafter monitor visual acuity monthly, if necessary subsequent doses may be given at least 1 month apart.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Diabetic macular oedema</p>\n<p outputclass=\"therapeuticIndication\">Macular oedema secondary to retinal vein occlusion (specialist use only)</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By intravitreal injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially 500&#8239;micrograms once a month, to be administered into the affected eye, monitor visual acuity monthly, continue treatment until visual acuity is stable for 3 consecutive months (discontinue treatment if no improvement in visual acuity after initial 3 injections), thereafter monitor visual acuity monthly, if necessary subsequent doses may be given at least 1 month apart.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Choroidal neovascularisation secondary to pathologic myopia (specialist use only)</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By intravitreal injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially 500&#8239;micrograms, to be administered as a single injection into the affected eye, monitor for disease activity monthly for first 2 months, then at least every 3 months thereafter during the first year, then as required, if necessary subsequent doses may be given at least 1 month apart.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Concomitant treatment of diabetic macular oedema, or macular oedema secondary to branch retinal vein occlusion, with laser photocoagulation (specialist use only)</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By intravitreal injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>500&#8239;micrograms, to be administered at least 30 minutes after laser photocoagulation.</p>\n</li>\n</ul>\n</section>\n</body>\n</topic>\n<topic id=\"PHP38906\" outputclass=\"contraindications\" rev=\"1.6\" parent=\"/drugs/ranibizumab\">\n<title>Contra-indications</title>\n<body>\n<section outputclass=\"contraindications\">\n<p>\n<ph outputclass=\"contraindication\">Ocular or periocular infection</ph>; <ph outputclass=\"contraindication\">severe intra-ocular inflammation</ph>; <ph outputclass=\"contraindication\">signs of irreversible ischaemic visual function loss in patients with retinal vein occlusion</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP38919\" outputclass=\"cautions\" rev=\"1.9\" parent=\"/drugs/ranibizumab\">\n<title>Cautions</title>\n<body>\n<section outputclass=\"cautions\">\n<p>\n<ph outputclass=\"caution\">Active systemic infection</ph>; <ph outputclass=\"caution\">diabetic macular oedema due to type 1 diabetes (limited information available)</ph>; <ph outputclass=\"caution\">diabetic patients with HbA<sub>1c </sub> over 12%</ph>; <ph outputclass=\"caution\">history of stroke</ph>; <ph outputclass=\"caution\">history of transient ischaemic attack</ph>; <ph outputclass=\"caution\">patients at risk of retinal pigment epithelial tear</ph>; <ph outputclass=\"caution\">previous intravitreal injections</ph>; <ph outputclass=\"caution\">proliferative diabetic retinopathy</ph>; <ph outputclass=\"caution\">retinal detachment or macular hole (discontinue treatment if rhegmatogenous retinal detachment or stage 3 or 4 macular holes develop)</ph>; <ph outputclass=\"caution\">uncontrolled hypertension</ph>\n</p>\n</section>\n<section outputclass=\"importantAdvice\">\n<title>Cautions, further information</title>\n<sectiondiv>\n<p>Ranibizumab is given by intravitreal injection by specialists. There is a potential risk of arterial thromboembolic events and non-ocular haemorrhage following the intravitreal injection of vascular endothelial growth factor inhibitors. Endophthalmitis can occur after intravitreal injections&#8212;patients should be advised to report any signs of infection immediately.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP38860\" outputclass=\"sideEffects\" rev=\"1.10\" parent=\"/drugs/ranibizumab\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"commonOrVeryCommon\">\n<p outputclass=\"title\">Common or very common</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Allergic skin reactions</ph>; <ph outputclass=\"sideEffect\">anaemia</ph>; <ph outputclass=\"sideEffect\">anterior chamber flare</ph>; <ph outputclass=\"sideEffect\">anxiety</ph>; <ph outputclass=\"sideEffect\">arthralgia</ph>; <ph outputclass=\"sideEffect\">blepharitis</ph>; <ph outputclass=\"sideEffect\">cataract</ph>; <ph outputclass=\"sideEffect\">conjunctival disorders</ph>; <ph outputclass=\"sideEffect\">conjunctivitis</ph>; <ph outputclass=\"sideEffect\">cough</ph>; <ph outputclass=\"sideEffect\">eye haemorrhage</ph>; <ph outputclass=\"sideEffect\">eyelid oedema</ph>; <ph outputclass=\"sideEffect\">headache</ph>; <ph outputclass=\"sideEffect\">iridocyclitis</ph>; <ph outputclass=\"sideEffect\">iritis</ph>; <ph outputclass=\"sideEffect\">nasopharyngitis</ph>; <ph outputclass=\"sideEffect\">nausea</ph>; <ph outputclass=\"sideEffect\">ocular discomfort</ph>; <ph outputclass=\"sideEffect\">photophobia</ph>; <ph outputclass=\"sideEffect\">photopsia</ph>; <ph outputclass=\"sideEffect\">posterior capsule opacification</ph>; <ph outputclass=\"sideEffect\">punctuate keratitis</ph>; <ph outputclass=\"sideEffect\">raised intra-ocular pressure</ph>; <ph outputclass=\"sideEffect\">retinal disorders</ph>; <ph outputclass=\"sideEffect\">urinary tract infection</ph>; <ph outputclass=\"sideEffect\">uveitis</ph>; <ph outputclass=\"sideEffect\">visual disturbance</ph>; <ph outputclass=\"sideEffect\">vitreous disorders</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"uncommon\">\n<p outputclass=\"title\">Uncommon</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Blindness</ph>; <ph outputclass=\"sideEffect\">corneal disorders</ph>; <ph outputclass=\"sideEffect\">hyphaema</ph>; <ph outputclass=\"sideEffect\">hypopyon</ph>; <ph outputclass=\"sideEffect\">iris adhesion</ph>; <ph outputclass=\"sideEffect\">keratopathy</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP38913\" outputclass=\"conceptionAndContraception\" parent=\"/drugs/ranibizumab\">\n<title>Conception and contraception</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Manufacturer recommends women use effective contraception during and for at least 3 months after treatment.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP38869\" outputclass=\"pregnancy\" parent=\"/drugs/ranibizumab\">\n<title>Pregnancy</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Manufacturer advises avoid unless potential benefit outweighs risk.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP38925\" outputclass=\"breastFeeding\" parent=\"/drugs/ranibizumab\">\n<title>Breast feeding</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Manufacturer advises avoid&#8212;no information available.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP38853\" outputclass=\"monitoringRequirements\" parent=\"/drugs/ranibizumab\">\n<title>Monitoring requirements</title>\n<body>\n<section outputclass=\"monitoringOfPatientParameters\">\n<sectiondiv>\n<p>Monitor intra-ocular pressure, perfusion of the optic nerve head, and for signs of ocular infection following injection.</p>\n<p>Monitor visual acuity, see individual indications and dose for frequency.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP38940\" outputclass=\"directionsForAdministration\" rev=\"1.8\" parent=\"/drugs/ranibizumab\">\n<title>Directions for administration</title>\n<body>\n<section>\n<sectiondiv>\n<p>For further information on administration, consult product literature.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP38847\" outputclass=\"nationalFunding\" rev=\"1.22\" parent=\"/drugs/ranibizumab\">\n<title>National funding/access decisions</title>\n<body>\r\n<section>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisals\">\r\n<p outputclass=\"title\">NICE technology appraisals (TAs)</p>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisal\">\r\n<p outputclass=\"fundingIdentifier\">NICE TA155</p>\r\n<sectiondiv>\r\n<p outputclass=\"title\">Ranibizumab and pegaptanib for the treatment of age-related macular degeneration (updated May 2012)</p>\r\n<p>Ranibizumab is recommended for the treatment of wet age-related macular degeneration if all of the following apply:</p>\r\n<ul>\r\n<li>the best corrected visual acuity is between 6/12 and 6/96;</li>\r\n<li>there is no permanent structural damage to the central fovea;</li>\r\n<li>the lesion size is less than or equal to 12 disc areas in greatest linear dimension;</li>\r\n<li>there is evidence of recent disease progression;</li>\r\n<li>the manufacturer provides ranibizumab with the discount agreed in the patient access scheme (as revised in 2012).</li>\r\n</ul>\r\n<p>Ranibizumab should only be continued in patients who maintain adequate response to therapy.</p>\n</sectiondiv>\n<xref format=\"html\" href=\"http://www.nice.org.uk/TA155\">www.nice.org.uk/TA155</xref>\n</sectiondiv>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisal\">\r\n<p outputclass=\"fundingIdentifier\">NICE TA274</p>\r\n<sectiondiv>\r\n<p outputclass=\"title\">Ranibizumab for the treatment of diabetic macular oedema (February 2013)</p>\r\n<p>Ranibizumab is recommended as an option for the treatment of visual impairment due to diabetic macular oedema only if:</p>\r\n<ul>\r\n<li> the eye has a central retinal thickness of 400&#8239;micrometres or more at the start of treatment <b>and</b>\r\n</li>\r\n<li>the manufacturer provides ranibizumab with the discount agreed in the patient access scheme (as revised in 2012).</li>\r\n</ul>\r\n<p>Patients currently receiving ranibizumab for treating visual impairment due to diabetic macular oedema whose disease does not meet the criteria should be able to continue treatment until they and their clinician consider it appropriate to stop.</p>\n</sectiondiv>\n<xref format=\"html\" href=\"http://www.nice.org.uk/TA274\">www.nice.org.uk/TA274</xref>\n</sectiondiv>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisal\">\r\n<p outputclass=\"fundingIdentifier\">NICE TA283</p>\r\n<sectiondiv>\r\n<p outputclass=\"title\">Ranibizumab for the treatment of visual impairment caused by macular oedema secondary to retinal vein occlusion (May 2013)</p>\r\n<p>Ranibizumab is recommended as an option for treating visual impairment caused by macular oedema:</p>\r\n<ul>\r\n<li>following central retinal vein occlusion <b>or</b>\r\n</li>\r\n<li>following branch retinal vein occlusion only if treatment with laser photocoagulation has not been beneficial, or when laser photocoagulation is not suitable because of the extent of macular haemorrhage <b>and</b>\r\n</li>\r\n<li>only if the manufacturer provides ranibizumab with the discount agreed in the patient access scheme revised in the context of NICE technology appraisal guidance 274.</li>\r\n</ul>\n</sectiondiv>\n<xref format=\"html\" href=\"http://www.nice.org.uk/TA283\">www.nice.org.uk/TA283</xref>\n</sectiondiv>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisal\">\r\n<p outputclass=\"fundingIdentifier\">NICE TA298</p>\r\n<sectiondiv>\r\n<p outputclass=\"title\">Ranibizumab for treating choroidal neovascularisation associated with pathological myopia (November 2013)</p>\r\n<p>Ranibizumab is recommended as an option for treating visual impairment due to choroidal neovascularisation secondary to pathological myopia when the manufacturer provides ranibizumab with the discount agreed in the patient access scheme.</p>\n</sectiondiv>\n<xref format=\"html\" href=\"http://www.nice.org.uk/TA298\">www.nice.org.uk/TA298</xref>\n</sectiondiv>\n</sectiondiv>\r\n<sectiondiv outputclass=\"smcDecisions\">\r\n<p outputclass=\"title\">Scottish Medicines Consortium (SMC) Decisions</p>\r\n<sectiondiv outputclass=\"smcDecision\">\r\n<sectiondiv>\r\n<p>The <i>Scottish Medicines Consortium</i> has advised (May 2007) that ranibizumab (<i>Lucentis</i>\n<tm tmtype=\"reg\"/>) is accepted for use within NHS Scotland for the treatment of neovascular (wet) age-related macular degeneration.</p>\n</sectiondiv>\n</sectiondiv>\r\n<sectiondiv outputclass=\"smcDecision\">\r\n<sectiondiv>\r\n<p>The <i>Scottish Medicines Consortium</i> has advised (October 2011 and April 2013) that ranibizumab (<i>Lucentis</i>\n<tm tmtype=\"reg\"/>) is accepted for use within NHS Scotland for the treatment of macular oedema secondary to branch or central retinal vein occlusion, and (November 2012) for restricted use for the treatment of visual impairment due to diabetic macular oedema in adults with best corrected visual acuity 75 Early Treatment Diabetic Retinopathy Study letters or less at baseline, and (October 2013) for the treatment of visual impairment due to choroidal neovascularisation secondary to pathologic myopia in adults; SMC advice is contingent upon the continuing availability of ranibizumab at the price agreed in the patient access scheme.</p>\n</sectiondiv>\n</sectiondiv>\n</sectiondiv>\n</section>\r\n\r\n</body>\n</topic>\n<topic id=\"PHP7169-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/ranibizumab\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP77495\" title=\"Solution for injection\" namespace=\"/drugs/ranibizumab/solution-for-injection\">Solution for injection</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78173\" namespace=\"/treatment-summaries/subfoveal-choroidal-neovascularisation\" title=\"Subfoveal choroidal neovascularisation\" count=\"3\" rel=\"backlink\">Subfoveal choroidal neovascularisation</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP77495\" namespace=\"/drugs/ranibizumab/solution-for-injection\" title=\"Solution for injection\" count=\"1\" rel=\"link\">Solution for injection</xref>\n</links>\n</topic>",
    "id": "PHP7169",
    "outputclass": "drug",
    "rev": "1.11",
    "type": "drug",
    "namespace": "/drugs/ranibizumab",
    "basename": "ranibizumab",
    "title": "RANIBIZUMAB",
    "vtmid": "425256004",
    "drugClassification": [
        "Vascular endothelial growth factor inhibitors"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Neovascular (wet) age-related macular degeneration (specialist use only)",
                        "html": "Neovascular (wet) age-related macular degeneration (specialist use only)"
                    }
                ],
                "specificity": {
                    "routes": [
                        "intravitreal injection"
                    ],
                    "textContent": "By intravitreal injection",
                    "html": "By intravitreal injection"
                },
                "adult": [
                    {
                        "textContent": "500 micrograms once a month, to be administered into the affected eye, monitor visual acuity monthly, continue treatment until visual acuity is stable for 3 consecutive months, thereafter monitor visual acuity monthly, if necessary subsequent doses may be given at least 1 month apart.",
                        "html": "<p>500&#8239;micrograms once a month, to be administered into the affected eye, monitor visual acuity monthly, continue treatment until visual acuity is stable for 3 consecutive months, thereafter monitor visual acuity monthly, if necessary subsequent doses may be given at least 1 month apart.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Diabetic macular oedema",
                        "html": "Diabetic macular oedema"
                    },
                    {
                        "textContent": "Macular oedema secondary to retinal vein occlusion (specialist use only)",
                        "html": "Macular oedema secondary to retinal vein occlusion (specialist use only)"
                    }
                ],
                "specificity": {
                    "routes": [
                        "intravitreal injection"
                    ],
                    "textContent": "By intravitreal injection",
                    "html": "By intravitreal injection"
                },
                "adult": [
                    {
                        "textContent": "Initially 500 micrograms once a month, to be administered into the affected eye, monitor visual acuity monthly, continue treatment until visual acuity is stable for 3 consecutive months (discontinue treatment if no improvement in visual acuity after initial 3 injections), thereafter monitor visual acuity monthly, if necessary subsequent doses may be given at least 1 month apart.",
                        "html": "<p>Initially 500&#8239;micrograms once a month, to be administered into the affected eye, monitor visual acuity monthly, continue treatment until visual acuity is stable for 3 consecutive months (discontinue treatment if no improvement in visual acuity after initial 3 injections), thereafter monitor visual acuity monthly, if necessary subsequent doses may be given at least 1 month apart.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Choroidal neovascularisation secondary to pathologic myopia (specialist use only)",
                        "html": "Choroidal neovascularisation secondary to pathologic myopia (specialist use only)"
                    }
                ],
                "specificity": {
                    "routes": [
                        "intravitreal injection"
                    ],
                    "textContent": "By intravitreal injection",
                    "html": "By intravitreal injection"
                },
                "adult": [
                    {
                        "textContent": "Initially 500 micrograms, to be administered as a single injection into the affected eye, monitor for disease activity monthly for first 2 months, then at least every 3 months thereafter during the first year, then as required, if necessary subsequent doses may be given at least 1 month apart.",
                        "html": "<p>Initially 500&#8239;micrograms, to be administered as a single injection into the affected eye, monitor for disease activity monthly for first 2 months, then at least every 3 months thereafter during the first year, then as required, if necessary subsequent doses may be given at least 1 month apart.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Concomitant treatment of diabetic macular oedema, or macular oedema secondary to branch retinal vein occlusion, with laser photocoagulation (specialist use only)",
                        "html": "Concomitant treatment of diabetic macular oedema, or macular oedema secondary to branch retinal vein occlusion, with laser photocoagulation (specialist use only)"
                    }
                ],
                "specificity": {
                    "routes": [
                        "intravitreal injection"
                    ],
                    "textContent": "By intravitreal injection",
                    "html": "By intravitreal injection"
                },
                "adult": [
                    {
                        "textContent": "500 micrograms, to be administered at least 30 minutes after laser photocoagulation.",
                        "html": "<p>500&#8239;micrograms, to be administered at least 30 minutes after laser photocoagulation.</p>"
                    }
                ]
            }
        ]
    },
    "contraindications": {
        "contraindications": [
            {
                "type": "contraindications",
                "textContent": "Ocular or periocular infection",
                "html": "Ocular or periocular infection"
            },
            {
                "type": "contraindications",
                "textContent": "severe intra-ocular inflammation",
                "html": "severe intra-ocular inflammation"
            },
            {
                "type": "contraindications",
                "textContent": "signs of irreversible ischaemic visual function loss in patients with retinal vein occlusion",
                "html": "signs of irreversible ischaemic visual function loss in patients with retinal vein occlusion"
            }
        ]
    },
    "cautions": {
        "cautions": [
            {
                "type": "cautions",
                "textContent": "Active systemic infection",
                "html": "Active systemic infection"
            },
            {
                "type": "cautions",
                "textContent": "diabetic macular oedema due to type 1 diabetes (limited information available)",
                "html": "diabetic macular oedema due to type 1 diabetes (limited information available)"
            },
            {
                "type": "cautions",
                "textContent": "diabetic patients with HbA1c over 12%",
                "html": "diabetic patients with HbA<sub>1c </sub> over 12%"
            },
            {
                "type": "cautions",
                "textContent": "history of stroke",
                "html": "history of stroke"
            },
            {
                "type": "cautions",
                "textContent": "history of transient ischaemic attack",
                "html": "history of transient ischaemic attack"
            },
            {
                "type": "cautions",
                "textContent": "patients at risk of retinal pigment epithelial tear",
                "html": "patients at risk of retinal pigment epithelial tear"
            },
            {
                "type": "cautions",
                "textContent": "previous intravitreal injections",
                "html": "previous intravitreal injections"
            },
            {
                "type": "cautions",
                "textContent": "proliferative diabetic retinopathy",
                "html": "proliferative diabetic retinopathy"
            },
            {
                "type": "cautions",
                "textContent": "retinal detachment or macular hole (discontinue treatment if rhegmatogenous retinal detachment or stage 3 or 4 macular holes develop)",
                "html": "retinal detachment or macular hole (discontinue treatment if rhegmatogenous retinal detachment or stage 3 or 4 macular holes develop)"
            },
            {
                "type": "cautions",
                "textContent": "uncontrolled hypertension",
                "html": "uncontrolled hypertension"
            }
        ],
        "importantAdvice": [
            {
                "type": "importantAdvice",
                "textContent": "Ranibizumab is given by intravitreal injection by specialists. There is a potential risk of arterial thromboembolic events and non-ocular haemorrhage following the intravitreal injection of vascular endothelial growth factor inhibitors. Endophthalmitis can occur after intravitreal injections&#8212;patients should be advised to report any signs of infection immediately.",
                "html": "<p>Ranibizumab is given by intravitreal injection by specialists. There is a potential risk of arterial thromboembolic events and non-ocular haemorrhage following the intravitreal injection of vascular endothelial growth factor inhibitors. Endophthalmitis can occur after intravitreal injections&#8212;patients should be advised to report any signs of infection immediately.</p>"
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "commonOrVeryCommon": [
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "Allergic skin reactions",
                        "html": "Allergic skin reactions",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "anaemia",
                        "html": "anaemia",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "anterior chamber flare",
                        "html": "anterior chamber flare",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "anxiety",
                        "html": "anxiety",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "arthralgia",
                        "html": "arthralgia",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "blepharitis",
                        "html": "blepharitis",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "cataract",
                        "html": "cataract",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "conjunctival disorders",
                        "html": "conjunctival disorders",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "conjunctivitis",
                        "html": "conjunctivitis",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "cough",
                        "html": "cough",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "eye haemorrhage",
                        "html": "eye haemorrhage",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "eyelid oedema",
                        "html": "eyelid oedema",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "headache",
                        "html": "headache",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "iridocyclitis",
                        "html": "iridocyclitis",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "iritis",
                        "html": "iritis",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "nasopharyngitis",
                        "html": "nasopharyngitis",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "nausea",
                        "html": "nausea",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "ocular discomfort",
                        "html": "ocular discomfort",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "photophobia",
                        "html": "photophobia",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "photopsia",
                        "html": "photopsia",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "posterior capsule opacification",
                        "html": "posterior capsule opacification",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "punctuate keratitis",
                        "html": "punctuate keratitis",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "raised intra-ocular pressure",
                        "html": "raised intra-ocular pressure",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "retinal disorders",
                        "html": "retinal disorders",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "urinary tract infection",
                        "html": "urinary tract infection",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "uveitis",
                        "html": "uveitis",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "visual disturbance",
                        "html": "visual disturbance",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "vitreous disorders",
                        "html": "vitreous disorders",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    }
                ],
                "uncommon": [
                    {
                        "type": "uncommon",
                        "textContent": "Blindness",
                        "html": "Blindness",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "corneal disorders",
                        "html": "corneal disorders",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "hyphaema",
                        "html": "hyphaema",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "hypopyon",
                        "html": "hypopyon",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "iris adhesion",
                        "html": "iris adhesion",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "keratopathy",
                        "html": "keratopathy",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    }
                ]
            }
        }
    },
    "conceptionAndContraception": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Manufacturer recommends women use effective contraception during and for at least 3 months after treatment.",
                "html": "<p>Manufacturer recommends women use effective contraception during and for at least 3 months after treatment.</p>"
            }
        ]
    },
    "pregnancy": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Manufacturer advises avoid unless potential benefit outweighs risk.",
                "html": "<p>Manufacturer advises avoid unless potential benefit outweighs risk.</p>"
            }
        ]
    },
    "breastFeeding": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Manufacturer advises avoid&#8212;no information available.",
                "html": "<p>Manufacturer advises avoid&#8212;no information available.</p>"
            }
        ]
    },
    "monitoringRequirements": {
        "patientParameters": [
            {
                "type": "patientParameters",
                "textContent": "Monitor intra-ocular pressure, perfusion of the optic nerve head, and for signs of ocular infection following injection.\n\nMonitor visual acuity, see individual indications and dose for frequency.",
                "html": "<p>Monitor intra-ocular pressure, perfusion of the optic nerve head, and for signs of ocular infection following injection.</p><p>Monitor visual acuity, see individual indications and dose for frequency.</p>"
            }
        ]
    },
    "directionsForAdministration": {
        "directionsForAdministration": [
            {
                "type": "directionsForAdministration",
                "textContent": "For further information on administration, consult product literature.",
                "html": "<p>For further information on administration, consult product literature.</p>"
            }
        ]
    },
    "nationalFunding": {
        "niceTechnologyAppraisals": [
            {
                "type": "niceTechnologyAppraisals",
                "references": [
                    {
                        "id": "http://www.nice.org.uk/TA155",
                        "label": "www.nice.org.uk/TA155"
                    }
                ],
                "fundingIdentifier": "NICE TA155",
                "textContent": "Ranibizumab and pegaptanib for the treatment of age-related macular degeneration (updated May 2012) Ranibizumab is recommended for the treatment of wet age-related macular degeneration if all of the following apply: the best corrected visual acuity is between 6/12 and 6/96; there is no permanent structural damage to the central fovea; the lesion size is less than or equal to 12 disc areas in greatest linear dimension; there is evidence of recent disease progression; the manufacturer provides ranibizumab with the discount agreed in the patient access scheme (as revised in 2012). Ranibizumab should only be continued in patients who maintain adequate response to therapy.\n\nwww.nice.org.uk/TA155",
                "html": "<p outputclass=\"title\">Ranibizumab and pegaptanib for the treatment of age-related macular degeneration (updated May 2012)</p> <p>Ranibizumab is recommended for the treatment of wet age-related macular degeneration if all of the following apply:</p> <ul> <li>the best corrected visual acuity is between 6/12 and 6/96;</li> <li>there is no permanent structural damage to the central fovea;</li> <li>the lesion size is less than or equal to 12 disc areas in greatest linear dimension;</li> <li>there is evidence of recent disease progression;</li> <li>the manufacturer provides ranibizumab with the discount agreed in the patient access scheme (as revised in 2012).</li> </ul> <p>Ranibizumab should only be continued in patients who maintain adequate response to therapy.</p><xref format=\"html\" href=\"http://www.nice.org.uk/TA155\">www.nice.org.uk/TA155</xref>"
            },
            {
                "type": "niceTechnologyAppraisals",
                "references": [
                    {
                        "id": "http://www.nice.org.uk/TA274",
                        "label": "www.nice.org.uk/TA274"
                    }
                ],
                "fundingIdentifier": "NICE TA274",
                "textContent": "Ranibizumab for the treatment of diabetic macular oedema (February 2013) Ranibizumab is recommended as an option for the treatment of visual impairment due to diabetic macular oedema only if: the eye has a central retinal thickness of 400 micrometres or more at the start of treatment and the manufacturer provides ranibizumab with the discount agreed in the patient access scheme (as revised in 2012). Patients currently receiving ranibizumab for treating visual impairment due to diabetic macular oedema whose disease does not meet the criteria should be able to continue treatment until they and their clinician consider it appropriate to stop.\n\nwww.nice.org.uk/TA274",
                "html": "<p outputclass=\"title\">Ranibizumab for the treatment of diabetic macular oedema (February 2013)</p> <p>Ranibizumab is recommended as an option for the treatment of visual impairment due to diabetic macular oedema only if:</p> <ul> <li> the eye has a central retinal thickness of 400&#8239;micrometres or more at the start of treatment <b>and</b> </li> <li>the manufacturer provides ranibizumab with the discount agreed in the patient access scheme (as revised in 2012).</li> </ul> <p>Patients currently receiving ranibizumab for treating visual impairment due to diabetic macular oedema whose disease does not meet the criteria should be able to continue treatment until they and their clinician consider it appropriate to stop.</p><xref format=\"html\" href=\"http://www.nice.org.uk/TA274\">www.nice.org.uk/TA274</xref>"
            },
            {
                "type": "niceTechnologyAppraisals",
                "references": [
                    {
                        "id": "http://www.nice.org.uk/TA283",
                        "label": "www.nice.org.uk/TA283"
                    }
                ],
                "fundingIdentifier": "NICE TA283",
                "textContent": "Ranibizumab for the treatment of visual impairment caused by macular oedema secondary to retinal vein occlusion (May 2013) Ranibizumab is recommended as an option for treating visual impairment caused by macular oedema: following central retinal vein occlusion or following branch retinal vein occlusion only if treatment with laser photocoagulation has not been beneficial, or when laser photocoagulation is not suitable because of the extent of macular haemorrhage and only if the manufacturer provides ranibizumab with the discount agreed in the patient access scheme revised in the context of NICE technology appraisal guidance 274.\n\nwww.nice.org.uk/TA283",
                "html": "<p outputclass=\"title\">Ranibizumab for the treatment of visual impairment caused by macular oedema secondary to retinal vein occlusion (May 2013)</p> <p>Ranibizumab is recommended as an option for treating visual impairment caused by macular oedema:</p> <ul> <li>following central retinal vein occlusion <b>or</b> </li> <li>following branch retinal vein occlusion only if treatment with laser photocoagulation has not been beneficial, or when laser photocoagulation is not suitable because of the extent of macular haemorrhage <b>and</b> </li> <li>only if the manufacturer provides ranibizumab with the discount agreed in the patient access scheme revised in the context of NICE technology appraisal guidance 274.</li> </ul><xref format=\"html\" href=\"http://www.nice.org.uk/TA283\">www.nice.org.uk/TA283</xref>"
            },
            {
                "type": "niceTechnologyAppraisals",
                "references": [
                    {
                        "id": "http://www.nice.org.uk/TA298",
                        "label": "www.nice.org.uk/TA298"
                    }
                ],
                "fundingIdentifier": "NICE TA298",
                "textContent": "Ranibizumab for treating choroidal neovascularisation associated with pathological myopia (November 2013) Ranibizumab is recommended as an option for treating visual impairment due to choroidal neovascularisation secondary to pathological myopia when the manufacturer provides ranibizumab with the discount agreed in the patient access scheme.\n\nwww.nice.org.uk/TA298",
                "html": "<p outputclass=\"title\">Ranibizumab for treating choroidal neovascularisation associated with pathological myopia (November 2013)</p> <p>Ranibizumab is recommended as an option for treating visual impairment due to choroidal neovascularisation secondary to pathological myopia when the manufacturer provides ranibizumab with the discount agreed in the patient access scheme.</p><xref format=\"html\" href=\"http://www.nice.org.uk/TA298\">www.nice.org.uk/TA298</xref>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ]
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP77495",
                "label": "Solution for injection",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ],
        "treatmentSummary": [
            {
                "id": "PHP78173",
                "label": "Subfoveal choroidal neovascularisation",
                "type": "treatmentSummary"
            }
        ]
    },
    "links": {
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP77495",
                "label": "Solution for injection",
                "type": "medicinalForm"
            }
        ]
    }
}